125
Participants
Start Date
August 30, 2019
Primary Completion Date
June 30, 2026
Study Completion Date
December 31, 2026
Ruvidar® (TLD-1433) Bladder infusion and PDT
Ruvidar® (TLD-1433) is infused into the bladder and treatment of bladder wall with light activation.
RECRUITING
Site 02-008 - MidLantic Urology, Bala-Cynwyd
TERMINATED
Site 02-009 - Virginia Urology, Richmond
RECRUITING
Site 02-006 - Carolina Urologic Research Center, Myrtle Beach
RECRUITING
Site 02-007 - Urology Associates, P. C, Nashville
RECRUITING
Site 02-011 - University of Wisconsin Health University Hospital, Madison
RECRUITING
Site 02-012 - University of Chicago, Chicago
RECRUITING
Site 02-010 - Urology San Antonio P. A, San Antonio
RECRUITING
Site 01-005 - The Vancouver Prostate Centre - Diamond Health Care Centre - Vancouver General Hospital, Vancouver
RECRUITING
Site 01-004 - Nova Scotia Health Authority - Centre for Applied Urology Research, Halifax
RECRUITING
Site 01-002- London Health Sciences Centre - Victoria Hospital, London
RECRUITING
Site 01-001 - University Health Network - Princess Margaret Cancer Centre, Toronto
RECRUITING
Site 01-003 - McGill University Health Centre - Glen-Cedars Cancer Centre, Montreal
Theralase® Technologies Inc.
INDUSTRY